Your browser doesn't support javascript.
loading
Injectable Systems for Intra-Articular Delivery of Mesenchymal Stromal Cells for Cartilage Treatment: A Systematic Review of Preclinical and Clinical Evidence.
Roffi, Alice; Nakamura, Norimasa; Sanchez, Mikel; Cucchiarini, Magali; Filardo, Giuseppe.
Afiliação
  • Roffi A; Laboratory of Nano-Biotechnology-IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. a.roffi@biomec.ior.it.
  • Nakamura N; Institute for Medical Science in Sports, Osaka Health Science University, Osaka 590-0496, Japan. norimasa.nakamura@ohsu.ac.jp.
  • Sanchez M; Arthroscopic Surgery Unit-UCA, Hospital Vithas San Jose, 01008 Vitoria-Gasteiz, Spain. mikel.sanchez@ucatrauma.com.
  • Cucchiarini M; Center of Experimental Orthopaedics, Saarland University Medical Center, 66421 Homburg/Saar, Germany. mmcucchiarini@hotmail.com.
  • Filardo G; Applied and Translational Research (ATR) Center-IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. ortho@gfilardo.com.
Int J Mol Sci ; 19(11)2018 Oct 25.
Article em En | MEDLINE | ID: mdl-30366400
ABSTRACT
Stem cell-based therapy is a promising approach to treat cartilage lesions and clinical benefits have been reported in a number of studies. However, the efficacy of cell injection procedures may be impaired by cell manipulation and damage as well as by cell dissemination to non-target tissues. To overcome such issues, mesenchymal stromal cell (MSC) delivery may be performed using injectable vehicles as containment systems that further provide a favorable cell microenvironment. The aim of this systematic review was to analyze the preclinical and clinical literature on platelet-rich plasma (PRP), hyaluronic acid (HA), and hydrogels for the delivery of MSCs. The systematic literature search was performed using the PubMed and Web of science databases with the following string "(stem cells injection) AND (platelet rich plasma OR PRP OR platelet concentrate OR biomaterials OR hyaluronic acid OR hydrogels)" 40 studies (19 preclinical and 21 clinical) met the inclusion criteria. This review revealed an increasing interest on the use of injectable agents for MSC delivery. However, while negligible adverse events and promising clinical outcomes were generally reported, the prevalence of low quality studies hinders the possibility to demonstrate the real benefits of using such injectable systems. Specific studies must be designed to clearly demonstrate the added benefits of these systems to deliver MSCs for the treatment of cartilage lesions and osteoarthritis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Mesenquimais Tipo de estudo: Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Mesenquimais Tipo de estudo: Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália